Halozyme Therapeutics (NASDAQ: HALO) announced a global collaboration and license agreement with AbbVie (NYSE: ABBV) to develop and commercialize products ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Halozyme Therapeutics' (HALO) Price Target Raised to $21 at JMP June 4, 2015 8:23 AM Halozyme Therapeutics (HALO) PT Lifted to $21 at Piper Jaffray on AbbVie DealJune 3, 2015 1:23 PM Halozyme Enters Into Global Collaboration and Licensing Agreement With AbbVieJune 3, 2015 8:30 AM Market Wrap: Intel, Altera Make it Official; Personal Spending Flatlines in April; ASCO Presentations in FocusJune 1, 2015 5:23 PM